Jazz Pharmaceuticals PLC - ESG Rating & Company Profile powered by AI
This Disclosure score includes seventeen UN SDGs including: 'Good Health & Wellbeing', 'Reduced Inequalities' and 'Partnerships for the Goals'. The report of Jazz Pharmaceuticals PLC was prepared by All Street Sevva using proprietary AI. Detailed Sustainability analysis of Jazz Pharmaceuticals PLC are reached by signing up for free.
Jazz Pharmaceuticals PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Jazz Pharmaceuticals PLC | 8.0 | High |
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Jazz Pharmaceuticals PLC have an accelerator or VC vehicle to help deliver innovation?
Does Jazz Pharmaceuticals PLC disclose current and historical energy intensity?
Does Jazz Pharmaceuticals PLC report the average age of the workforce?
Does Jazz Pharmaceuticals PLC reference operational or capital allocation in relation to climate change?
Does Jazz Pharmaceuticals PLC disclose its ethnicity pay gap?
Does Jazz Pharmaceuticals PLC disclose cybersecurity risks?
Does Jazz Pharmaceuticals PLC offer flexible work?
Does Jazz Pharmaceuticals PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Jazz Pharmaceuticals PLC disclose the number of employees in R&D functions?
Does Jazz Pharmaceuticals PLC conduct supply chain audits?
Does Jazz Pharmaceuticals PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Jazz Pharmaceuticals PLC conduct 360 degree staff reviews?
Does Jazz Pharmaceuticals PLC disclose the individual responsible for D&I?
Does Jazz Pharmaceuticals PLC disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Jazz Pharmaceuticals PLC disclose current and / or historical scope 2 emissions?
Does Jazz Pharmaceuticals PLC disclose water use targets?
Does Jazz Pharmaceuticals PLC have careers partnerships with academic institutions?
Did Jazz Pharmaceuticals PLC have a product recall in the last two years?
Does Jazz Pharmaceuticals PLC disclose incidents of discrimination?
Does Jazz Pharmaceuticals PLC allow for Work Councils/Collective Agreements to be formed?
Has Jazz Pharmaceuticals PLC issued a profit warning in the past 24 months?
Does Jazz Pharmaceuticals PLC disclose parental leave metrics?
Does Jazz Pharmaceuticals PLC disclose climate scenario or pathway analysis?
Does Jazz Pharmaceuticals PLC disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Jazz Pharmaceuticals PLC disclose the pay ratio of women to men?
Does Jazz Pharmaceuticals PLC support suppliers with sustainability related research and development?
Does Jazz Pharmaceuticals PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Jazz Pharmaceuticals PLC reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Jazz Pharmaceuticals PLC involved in embryonic stem cell research?
Does Jazz Pharmaceuticals PLC disclose GHG and Air Emissions intensity?
Does Jazz Pharmaceuticals PLC disclose its waste policy?
Does Jazz Pharmaceuticals PLC report according to TCFD requirements?
Does Jazz Pharmaceuticals PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Jazz Pharmaceuticals PLC disclose energy use targets?
Does Jazz Pharmaceuticals PLC disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Jazz Pharmaceuticals PLC have a policy relating to cyber security?
Have a different question?
Potential Risks for Jazz Pharmaceuticals PLC
These potential risks are based on the size, segment and geographies of the company.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.